The Sunnyvale, California-based business, which trades on the Nasdaq under the ticker CBRS, has been doing what very few pure-play AI hardware names have been able to do: expanding rapidly while managing to remain undervalued by a larger audience. Q2 2026 revenue was $180 million, a 74% increase over the previous year. According to reports, cloud revenue increased by 287%. These figures are not insignificant. Nevertheless, the stock recently fell 14% following earnings, which alarmed some observers and perplexed others.
The odd tension in that is difficult to ignore. A company achieves triple-digit cloud growth, exceeds revenue projections by 8.4%, and is sold off by the market. The most plausible reason is that investors had higher expectations or noticed something in the guidance that seemed uncertain. In a market that penalizes any deviation, no matter how slight, there is a feeling that the stock has been priced for perfection.
The company’s flagship partnership with OpenAI contributes to some of that pressure. Cerebras and OpenAI signed a Master Relationship Agreement in late 2025, which requires OpenAI to purchase 750 megawatts of inference capacity by 2028. A $1 billion working capital loan was included in the deal to support manufacturing. That arrangement is both spectacular and dangerous. One customer, one contract, one massive reliance. What would happen if OpenAI’s own course or that relationship changed? It’s still unclear if the backlog, which is estimated to be $25.4 billion, represents a single wager dressed up in big numbers or if it clearly translates into long-term, diversified revenue.
Wafer-scale chip architecture, which essentially places the entire chip on a single silicon wafer rather than piecing together smaller dies, is the foundation of Cerebras, which was founded in 2015 by Andrew Feldman. The technical benefits are significant, especially in terms of inference speed and power efficiency. Engineers and investors alike focused on the intricacies of wafer-scale engineering and how it stacks up against well-established competitors during a recent Q&A session with the company’s CTO. The interest itself conveys a message. People are observing.
The insider trading data is more difficult to interpret. Insiders have completed 288 transactions in CBRS stock over the last six months, all of which were sales and none of which were purchases. For an estimated $168 million, the CTO sold more than 811,000 shares. About $64 million worth of shares were sold by the CEO. Sustained selling is not always what it appears to be, particularly when lockup periods end following an IPO. However, it raises a question that most ordinary investors won’t voice: wouldn’t at least one of the product’s developers be purchasing if they thought the stock was inexpensive?
In the meantime, institutions are going in the complete opposite direction. In the second quarter of 2026, FMR LLC added more than 8.4 million shares. Seven million more were added by Coatue Management. Important positions were started by Morgan Stanley, JPMorgan, and Capital World Investors. One of the more peculiar dynamics in the stock at the moment is the divergence between institutional buying and insider selling. The average Wall Street price target is around $296, which is significantly higher than the current price of the stock, which has recently been in the $195–$205 range. Needham analysts have a buy rating. $385 is the 52-week high. There is space for the stock in both directions.
Cerebras has not yet turned a profit. Since there are no earnings to calculate, the P/E ratio is not applicable. That’s acceptable for a business at this point, but it implies that the valuation is solely based on narrative momentum and forward expectations. A $46.6 billion market capitalization for a business that is still losing money is the kind of math that calls for patience, faith, or both. Cathie Wood’s recent purchase of $6.5 million worth of CBRS shares indicates that astute investors are prepared to maintain that conviction. It will take some time to determine whether they are correct or not.
In all honesty, the current state of Cerebras stock is both genuinely intriguing and genuinely uncertain. The technology is genuine. The increase in revenue is genuine. The collaboration with OpenAI is genuine. However, the picture isn’t as clear-cut as the headlines imply due to customer concentration, continuous losses, and significant insider selling. Observing how this develops over the coming quarters will reveal a lot about Cerebras as well as the market’s perception of AI infrastructure firms that are still developing.
